Armēnija - angļu - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smithkline beecham limited - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets film-coated - 500mg+ 125mg

Armēnija - angļu - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smithkline beecham limited - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets film-coated - 875mg+ 125mg

Izraēla - angļu - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as sodium; clavulanic acid as potassium clavulanate - powder for solution for inj/inf - amoxicillin as sodium 1000 mg; clavulanic acid as potassium clavulanate 200 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children: severe infections of the ear, nose and throat (such as mastoiditis, peritonsillar infections, epiglottitis, and sinusitis when accompanied by severe systemic signs and symptoms), acute exacerbations of chronic bronchitis (adequately diagnosed), community acquired pneumonia. cystitis, pyelonephritis, skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis, bone and joint infections, in particular osteomyelitis, intra-abdominal infections, female genital infections. prophylaxis against infections associated with major surgical procedures in adults, such as those involving the: gastrointestinal tract, pelvic cavity, head and neck, biliary tract surgery.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lactamase producing organisms susceptible to augmentin tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; dimeticone 5000; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lact

Armēnija - angļu - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smithkline beecham limited - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets film-coated - 250mg+ 125mg

Izraēla - angļu - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - film coated tablets - amoxicillin as trihydrate 250 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children :• acute bacterial sinusitis (adequately diagnosed)• otitis media infection• acute pharyngitis• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 151.92 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 286.9 mg (equivalent: amoxicillin trihydrate, qty 250 mg); potassium clavulanate, quantity: 149.5 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; dimeticone 200; titanium dioxide; propylene glycol; hypromellose; ethylcellulose - augmentin is indicated in the treatment of the following infections when caused by augmentin sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing s. aureus, e. coli and klebsiella spp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis & klebsiella spp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h.influenzae and m.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and s. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h.influenzae and m.catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is reason to believe an infection may involve any

Izraēla - angļu - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - film coated tablets - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - ampicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children :• acute bacterial sinusitis (adequately diagnosed)• acute otitis media• acute exacerbations of chronic bronchitis (adequately diagnosed)• community acquired pneumonia• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.• bone and joint infections, in particular osteomyelitis.